US92790C1045 - Common Stock
VIRIDIAN THERAPEUTICS INC
NASDAQ:VRDN (5/3/2024, 7:25:16 PM)
After market: 16.3 +0.9 (+5.84%)15.4
+0.82 (+5.62%)
Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. The company is headquartered in Waltham, Massachusetts and currently employs 86 full-time employees. The company went IPO on 2014-06-18. The firm is engaged in developing three product candidates, VRDN-001, VRDN-002, and VRDN-003, that is developed for intravenous (IV) or subcutaneous administration to treat patients who suffer from thyroid eye disease (TED). Its lead product candidate, VRDN-001, is a differentiated humanized monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the TED. The company has initiated a Phase I/II clinical trial of VRDN-001. Its second product candidate, VRDN-002, is a distinct IGF-1R antibody that incorporates half-life extension technology, and is designed to support administration as a convenient, low volume, subcutaneous injection to treat patients who suffer from TED. VRDN-003 is an anti-IGF-1R monoclonal antibody with the same amino acid sequence as VRDN-001.
VIRIDIAN THERAPEUTICS INC
221 Crescent Street, Bldg. 17, Suite 401
Waltham MASSACHUSETTS 80301
P: 16172724600
CEO: Jonathan Violin
Employees: 86
/PRNewswire/ -- Kaskela Law LLC announces that it is investigating Viridian Therapeutics, Inc. (NASDAQ: VRDN) ("Viridian") on behalf of the company's...
Here you can normally see the latest stock twits on VRDN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: